(Q21710738)

PubMed

PubMed publication ID

7 February 2023

Ronald S Swerdloff

2

Ronald S

Swerdloff

1 reference

PubMed

PubMed publication ID

15105800

American Journal of Obstetrics and Gynecology

7 February 2023

language of work or name

English

0 references

publication date

April 2004

0 references

published in

0 references

volume

190

0 references

issue

4

0 references

page(s)

S60-S68

0 references

cites work

Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Use of low-dosage oral cyproterone acetate as a male contraceptive.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Vasal sterilization in China

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Contraceptive efficacy of testosterone-induced azoospermia in normal men

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Does constant infusion of gonadotropin-releasing hormone agonist lead to greater suppression of gonadal function in man than its intermittent administration?

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Suppression of sperm function by depot medroxyprogesterone acetate and testosterone enanthate in steroid male contraception.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Endocrine regulation of testicular function in men: implications for contraceptive development

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Inactivating FSH receptor mutations and gonadal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Prospects for new hormonal male contraceptives.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Potential of norethisterone enanthate for male contraception: pharmacokinetics and suppression of pituitary and gonadal function

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Combination of subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel for male hormonal contraception

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Mutations in the follicle-stimulating hormone-beta (FSH beta) and FSH receptor genes in mice and humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary–testicular axis in normal men*

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Significance of apoptosis in the temporal and stage-specific loss of germ cells in the adult rat after gonadotropin deprivation

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Hormonal effects of GnRH agonist in the human male: II. Testosterone enhances gonadotrophin suppression induced by GnRH agonist

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Sperm function in Indonesian men treated with testosterone enanthate

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Testosterone dose-response relationships in healthy young men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Temporal and stage-specific changes in spermatogenesis of rat after gonadotropin deprivation by a potent gonadotropin-releasing hormone antagonist treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Testicular heat exposure enhances the suppression of spermatogenesis by testosterone in rats: the "two-hit" approach to male contraceptive development

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Spermiation failure is a major contributor to early spermatogenic suppression caused by hormone withdrawal in adult rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

A Clinical Trial of 7α-Methyl-19-Nortestosterone Implants for Possible Use as a Long-Acting Contraceptive for Men

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Contraceptive efficacy of a depot progestin and androgen combination in men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Acute and specific impairment of spermatogonial development by GnRH antagonist-induced gonadotrophin withdrawal in the adult macaque (Macaca fascicularis).

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Contraceptive failure in the United States: a critical review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021

Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FJ.AJOG.2004.01.057

7 January 2021